Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Capital Expenditures (2016 - 2025)

Rocket Pharmaceuticals (RCKT) has disclosed Capital Expenditures for 10 consecutive years, with -$360000.0 as the latest value for Q4 2025.

  • Quarterly Capital Expenditures fell 350.0% to -$360000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $280000.0 through Sep 2025, up 102.68% year-over-year, with the annual reading at $185000.0 for FY2024, 82.82% down from the prior year.
  • Capital Expenditures hit -$360000.0 in Q4 2025 for Rocket Pharmaceuticals, down from -$54000.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $5.3 million in Q2 2023 to a low of -$10.7 million in Q4 2023.
  • Historically, Capital Expenditures has averaged $548850.0 across 5 years, with a median of $974500.0 in 2021.
  • Biggest five-year swings in Capital Expenditures: skyrocketed 4152.94% in 2021 and later tumbled 350.0% in 2025.
  • Year by year, Capital Expenditures stood at $2.0 million in 2021, then crashed by 265.9% to -$3.3 million in 2022, then plummeted by 228.59% to -$10.7 million in 2023, then surged by 99.25% to -$80000.0 in 2024, then crashed by 350.0% to -$360000.0 in 2025.
  • Business Quant data shows Capital Expenditures for RCKT at -$360000.0 in Q4 2025, -$54000.0 in Q3 2025, and $50000.0 in Q2 2025.